Loading…
Loading…
QBIO (Q BioMed Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
QBIO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for QBIO and 80,000+ other tickers.
See exactly how QBIO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for QBIO and 80,000+ other tickers.
Q BioMed Inc. functions as a biomedical accelerator and developer, actively licensing, acquiring, and supplying resources to firms within the life sciences and healthcare sectors. Its commercial portfolio includes Metastron (Strontium Chloride SR89), a radiopharmaceutical designed to alleviate pain associated with metastatic bone cancer. Additionally, Q BioMed is advancing a pipeline of therapeutic candidates, including Man-01, a pre-clinical compound aimed at primary open-angle glaucoma; QBM-001, intended for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, which targets…
GeneDx (NASDAQ: WGS - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings. Risk and Volatility GeneDx has a beta of 2.17,
Establishment Labs (NASDAQ: ESTA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk. Valuation and Earnings This table compares Establishment Labs
Auna (NYSE: AUNA - Get Free Report) and Q Biomed (OTCMKTS:QBIO - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation and dividends. Volatility and Risk Auna has a beta of 2.26,
Q Biomed (OTCMKTS:QBIO - Get Free Report) and GoodRx (NASDAQ: GDRX - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Institutional and Insider Ownership 63.8% of GoodRx shares are
Q Biomed (OTCMKTS:QBIO - Get Free Report) and SBC Medical Group (NASDAQ: SBC - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Earnings and Valuation This table compares Q